

ASX Release

Date: 2 April 2024

Section 708A(5)(e) disclosure notice – Exercise of Restricted Stock Units

Imugene Limited (ASX: IMU) (**Imugene** or **Company**) has issued 1,439,248 fully paid ordinary shares in respect of the exercise of 1,439,248 Restricted Stock Units, as per the Appendix 2A released today.

Details of the securities issued are as follows:

Class of securities:	Ordinary shares
ASX Code of the securities:	IMU
Date of the issue or expected issue of the securities:	28 March 2024
Total number of securities issued or expected to be issued:	1,439,248

The Company gives notice pursuant to section 708(5)(e) of the *Corporations Act 2001* Cth (**Corporations Act**) that:

1. the above securities have been issued without disclosure to investors under part 6D.2 Corporations Act;
2. this notice is given under section 708A(5)(e) and in accordance with section 708A(6) Corporations Act;
3. at the date of this notice, the Company has complied with:
 - a. the provisions of chapter 2M Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A Corporations Act; and
4. at the date of this notice, there is no information required to be disclosed by the Company which is 'excluded information' (as defined in sections 708A(7) and 708A(8) Corporations Act).



For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited
Follow us on Twitter @TeamImugene
Watch us on YouTube @ImugeneLimited
Join us on InvestorHub; investorhub.imugene.com

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and



resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Company Secretary, Imugene Limited.